Equity Overview
Price & Market Data
Price: $0.65
Daily Change: -$0.128 / 19.74%
Daily Range: $0.61 - $0.757
Market Cap: $11,057,193
Daily Volume: 3,249,804
Performance Metrics
1 Week: -21.54%
1 Month: -78.35%
3 Months: -81.58%
6 Months: -84.63%
1 Year: -94.00%
YTD: -92.57%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country:
Details
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.